Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells

Abstract

Berberine, a natural isoquinoline alkaloid derived fromCoptidis rhizoma has long been used in traditional medicine and has recently attracted attention for its potential role in cancer therapy. Emerging evidence suggests that berberine can inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of lipid metabolism that has also been implicated in tumor biology. While the role of PCSK9 in cardiovascular diseases is well established, its contribution to cancer progression and therapeutic response remains incompletely understood. Here, we investigated whether berberine-mediated inhibition of PCSK9 could enhance the efficacy of chemotherapeutic agents. Berberine reduced PCSK9 expression at both mRNA and protein levels and increased LDLR abundance in A431 cells, which exhibit high basal PCSK9 expression. Functionally, berberine decreased cell viability in a dose-dependent manner and exhibited a strong synergistic interaction with etoposide, according to the HSA synergy score. Mechanistic analyses indicated that berberine enhances etoposide-induced cytotoxicity, at least in part by delaying the resolution of DNA-damage associated signals. Importantly, genetic silencing of PCSK9 recapitulated the sensitizing effect of berberine, while palmatine, a structurally related compound with lower efficacy in reducing PCSK9 levels, showed decreased synergy with etoposide, although evaluated under a different range of concentrations. Collectively, these findings support a role for PCSK9 in modulating cellular sensitivity to etoposide and suggest that berberine may act as a potential adjuvant in this context.

Malignant transformation of an intracranial epidermoid cyst into squamous cell carcinoma: a case report and systematic review
Lorraine Edna Onzere, Jinan Ma, Elihuruma Eliufoo Stephano +4
Frontiers in Oncology28 Oct 2026Peer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossref
Development and characterization of an Eugenol–Shilajit–Chitosan nano-gel composite with anticancer activity against oral squamous cell carcinoma
Sultan Aati, Ahmed Hamd, Abdullah Alshamrani +6
Scientific Reports24 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textPharmacology & toxicologyCrossref
Role of Ferroptosis in Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Systematic Review of Preclinical Studies
Cintia Marques, Everton Morais, Nicolly Felipe-Moreira +5
International Journal of Molecular Sciences27 Oct 2026Peer-reviewedCC BY 4.0General medicineCrossref
Hollow fiber assay microtube array membrane (MTAM-HFA) for personalized anticancer drug screening in selection of concurrent chemoradiotherapy in oral squamous cell carcinoma.
Shan-Ju Chou, Po-Chih Hsu, Chee Ho Chew +7
Journal of dental sciences1 Oct 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma
Ruyan Li, Zihao Heng, Xi Cheng
Frontiers in Pharmacology16 Oct 2026Peer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC

Cite

BibTeX RIS

BibTeX

@article{cinar2026berberine,
  title = {{Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells}},
  author = {Zeynep Özlem Cinar and Valerija Šatrova and Akshay Kumar Vijaya and Milda Babonaitė-Aleksieju̅nė and Goda Glebavičiu̅tė and Aurelijus Burokas and Giulio Preta},
  journal = {ACS omega},
  year = {2026},
  month = oct,
  doi = {10.1021/acsomega.6c06421},
  url = {https://europepmc.org/article/PMC/PMC13670754},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells
AU  - Zeynep Özlem Cinar
AU  - Valerija Šatrova
AU  - Akshay Kumar Vijaya
AU  - Milda Babonaitė-Aleksieju̅nė
AU  - Goda Glebavičiu̅tė
AU  - Aurelijus Burokas
AU  - Giulio Preta
PY  - 2026
DA  - 2026/10/02
JO  - ACS omega
DO  - 10.1021/acsomega.6c06421
UR  - https://europepmc.org/article/PMC/PMC13670754
AB  - Berberine, a natural isoquinoline alkaloid derived fromCoptidis rhizoma has long been used in traditional medicine and has recently attracted attention for its potential role in cancer therapy. Emerging evidence suggests that berberine can inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of lipid metabolism that has also been implicated in tumor biology. While the role of PCSK9 in cardiovascular diseases is well established, its contribution to cancer progression and therapeutic response remains incompletely understood. Here, we investigated whether berberine-mediated inhibition of PCSK9 could enhance the efficacy of chemotherapeutic agents. Berberine reduced PCSK9 expression at both mRNA and protein levels and increased LDLR abundance in A431 cells, which exhibit high basal PCSK9 expression. Functionally, berberine decreased cell viability in a dose-dependent manner and exhibited a strong synergistic interaction with etoposide, according to the HSA synergy score. Mechanistic analyses indicated that berberine enhances etoposide-induced cytotoxicity, at least in part by delaying the resolution of DNA-damage associated signals. Importantly, genetic silencing of PCSK9 recapitulated the sensitizing effect of berberine, while palmatine, a structurally related compound with lower efficacy in reducing PCSK9 levels, showed decreased synergy with etoposide, although evaluated under a different range of concentrations. Collectively, these findings support a role for PCSK9 in modulating cellular sensitivity to etoposide and suggest that berberine may act as a potential adjuvant in this context.
SN  - 2470-1343
ER  -

Abstract

Related

Cite